About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDPhase 3

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)

A Randomized, Double-Blind, Placebo-Controlled Efficacy Study of The Neurokinin-1 Receptor Antagonist VLY-686 in Patients With Atopic Dermatitis

NCT03568331•Vanda Pharmaceuticals

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Atopic Dermatitis

Interventions

Tradipitant

Placebo

Locations

70

United States

Locations (70)

Vanda Investigational Site

Birmingham, Alabama, United States

Vanda Investigational Site

Birmingham, Alabama, United States

Vanda Investigational Site

Tempe, Arizona, United States

Vanda Investigational Site

Encino, California, United States

Vanda Investigational Site

Fountain Valley, California, United States

Vanda Investigational Site

Fremont, California, United States

Key Dates

Start Date

July 9, 2018

Primary Completion Date

December 27, 2019

Completion Date

December 27, 2019

Last Updated

May 13, 2024

Related Studies

RECRUITINGPhase 1

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT07262983

Hyper IgE Syndrome From STAT3 MutationJob s Syndrome+3 more

RECRUITINGPhase 3

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

NCT06389136

Atopic Dermatitis

RECRUITINGPhase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT06342713

Healthy ParticipantsHealthy Subjects+5 more

RECRUITINGPhase 2

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

NCT07223697

Atopic Dermatitis

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

NCT07290803

Atopic Dermatitis

RECRUITINGPhase 3

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

NCT07265479

Atopic Dermatitis

View all related studies

Sponsors

Lead Sponsor

Vanda Pharmaceuticals

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 13, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions